Clinical applications of palifermin: amelioration of oral mucositis and other potential indications - Wikidata - awgldk - TriplyDB

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications

http://www.wikidata.org/entity/Q26852139

about

Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients New approaches to radiation protection Radiation countermeasure agents: an update (2011-2014)Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Radioprotective agents for radiation therapy: future trends.A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in lar Palifermin and Chlorhexidine Mouthwashes in Prevention of Chemotherapy-Induced Mucositis in Children with Acute Lymphocytic Leukemia: a Randomized Controlled Trial.Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients.A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.Radioprotective Effects of Dermatan Sulfate in a Preclinical Model of Oral Mucositis-Targeting Inflammation, Hypoxia and Junction Proteins without Stimulating Proliferation.FGF Family: From Drug Development to Clinical Application

P2860

Q26750933-3B310233-D2BD-4589-8B43-7CCB678117CC Q26799602-1A1FE8BE-2C5A-4DA3-80F5-8D77F2C463FB Q27005588-3AFD7102-8E13-46D1-BA3A-2B91735DE5D4 Q35626587-EBC23350-F697-4028-96A3-58D72CF189C2 Q36379148-F9C1922C-F6CD-40FE-86CA-7BB894B77431 Q38294594-A1B02FD7-6660-4FA9-A9CF-3C4777004462 Q38665691-38D29418-3089-4B71-ABBA-7C195FC407E6 Q39109668-CC74335A-E9C1-49E2-9047-8CF3303BE674 Q39191655-965B5197-6485-4E9F-ADD3-6FA72B0F1CC3 Q52560942-D5646B22-7B8B-4564-9686-E8C79D8B135E Q55656164-15B6117D-2B86-4CF1-BD33-6457C79EF63B Q57116705-19FC2B10-F725-4A6E-9A0B-C875CDF4C92F

P2860

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications

http://www.wikidata.org/entity/Q26852139

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clinical applications of palif ...... nd other potential indications

@ast

Clinical applications of palif ...... nd other potential indications

@en

Clinical applications of palif ...... nd other potential indications

@nl

type

label

Clinical applications of palif ...... nd other potential indications

@ast

Clinical applications of palif ...... nd other potential indications

@en

Clinical applications of palif ...... nd other potential indications

@nl

prefLabel

Clinical applications of palif ...... nd other potential indications

@ast

Clinical applications of palif ...... nd other potential indications

@en

Clinical applications of palif ...... nd other potential indications

@nl

P1433

Q26852139-9C8CD80B-829E-4417-BE9A-A6C6D587AF79

P1476

Q26852139-3520FF6D-D362-4760-9BCF-4F491F6137FC

P2093

Q26852139-25418CF1-E9CF-4AAD-966B-F086398F4204

Q26852139-4CD1653D-96C8-4814-8A9B-101C6B1843C9

Q26852139-68A37821-89F6-49CD-88F6-6EFAC965BDA9

Q26852139-932B217C-E999-4ABE-B706-BA0F1F096E8D

P275

Q26852139-5FA889D9-F07C-435A-911C-5994C07135A9

P2860

Q26852139-0654287A-F5F1-492F-A90B-4740599C39BC

Q26852139-1E374517-1DC5-4520-94C1-C620462016E8

Q26852139-1EC83B94-21F6-455F-BA0C-DF8110891899

Q26852139-1F2B2FFA-B841-42E8-9DDB-BEDA9203B02D

Q26852139-26E79650-6982-496F-8708-E4716B6B0A0D

Q26852139-2EF1B854-10CB-4B70-87CE-73FCA4095FEE

Q26852139-31FC0825-878B-4DA5-A98C-6AE3322A3956

Q26852139-35969F5C-98E4-40D3-9D41-0AB019644119

Q26852139-38DFFC3A-9C61-43A1-9B6E-E0EE215023BA

Q26852139-3A3001DF-C268-41E8-BA83-36AB32692F97

P304

Q26852139-7E71AD41-BD02-4222-8184-BA306AFA9F0E

P31

Q26852139-50039571-4ABF-4C4B-BCA8-1EDAEF4D3991

Q26852139-7F2BD74E-1C8F-4BFD-9532-E6248849515B

P3181

Q26852139-8D3845B0-1A1E-46B1-818B-2BF58760A57C

P356

Q26852139-0F2C075B-EF78-4B79-8A32-C7717CA56664

P407

Q26852139-D042A1E4-6E5F-47F1-863A-28B55540F18F

P433

Q26852139-51A2D2B4-7F55-420C-8DAC-C14EBBC7D4E7

P478

Q26852139-BCC60496-CC6F-4A51-A693-6EC561EF2C18

P50

Q26852139-34530D30-3F69-40A4-89F9-412F7D839218

P5008

Q26852139-348D6055-33DD-4221-ADE6-361CF6C696C1

P577

Q26852139-6A006D41-2731-414B-ADDB-57C4FC97EA8D

Q26852139-6DE54905-F6DD-4A16-82B6-F79A25F86B03

P5875

Q26852139-4E8FF8EE-48AF-4762-97C7-4EB0FE965663

P698

Q26852139-D200902C-D518-4721-97E6-BC7F11257FAF

P921

Q26852139-2CF3B5E5-C7E9-41DD-A270-10554096B38A

Q26852139-428825F4-9333-4624-B78A-76619C10CED2

Q26852139-94F12D29-D9BB-4883-8EA7-B5216A68D2B7

P932

Q26852139-64122A5E-37B5-42BD-AD1B-333FFA06891C

P3181

P356

P1433

Journal of Cellular and Molecular Medicine

P1476

Clinical applications of palif ...... nd other potential indications

@en

P2093

Dietmar P Berger

http://www.w3.org/2001/XMLSchema#string

Jenna D Goldberg

http://www.w3.org/2001/XMLSchema#string

Marcel R M van den Brink

http://www.w3.org/2001/XMLSchema#string

Saroj Vadhan-Raj

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Purification and characterization of a newly identified growth factor specific for epithelial cells

Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2)

Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis

Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair

Palifermin for oral mucositis after intensive therapy for hematologic cancers

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.

Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.

P304

1371-1384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2222438

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/JCMM.12169

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Miguel-Angel Perales

P5008

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258765381

http://www.w3.org/2001/XMLSchema#string

P698

24251854

http://www.w3.org/2001/XMLSchema#string

P921

head and neck cancer

P932

4117550

http://www.w3.org/2001/XMLSchema#string